Sialylated glycans on the surface of mammalian cells act as part of a "self-associated molecular pattern," helping the immune system to recognize "self" from "altered self" or "nonself." To escape the host immune system, some bacterial pathogens have evolved biosynthetic pathways for host-like sialic acids, whereas others recruited host sialic acids for decorating their surfaces. Prions lack nucleic acids and are not conventional pathogens. Nevertheless, prions might use a similar strategy for invading and colonizing the lymphoreticular system. Here we show that the sialylation status of the infectious, disease-associated state of the prion protein (PrP Sc ) changes with colonization of secondary lymphoid organs (SLOs). As a result, spleen-derived PrP Sc is more sialylated than brain-derived PrP
Sialylated glycans on the surface of mammalian cells act as part of a "self-associated molecular pattern," helping the immune system to recognize "self" from "altered self" or "nonself." To escape the host immune system, some bacterial pathogens have evolved biosynthetic pathways for host-like sialic acids, whereas others recruited host sialic acids for decorating their surfaces. Prions lack nucleic acids and are not conventional pathogens. Nevertheless, prions might use a similar strategy for invading and colonizing the lymphoreticular system. Here we show that the sialylation status of the infectious, disease-associated state of the prion protein (PrP Sc ) changes with colonization of secondary lymphoid organs (SLOs). As a result, spleen-derived PrP Sc is more sialylated than brain-derived PrP Sc 
. Enhanced sialylation of PrP
Sc is recapitulated in vitro by incubating brain-derived PrP Sc with primary splenocytes or cultured macrophage RAW 264.7 cells. General inhibitors of sialyltranserases (STs), the enzymes that transfer sialic acid residues onto terminal positions of glycans, suppressed extrasialylation of PrP Sc . A fluorescently labeled precursor of sialic acid revealed ST activity associated with RAW macrophages. This study illustrates that, upon colonization of SLOs, the sialylation status of prions changes by host STs. We propose that this mechanism is responsible for camouflaging prions in SLOs and has broad implications.
prions | prion diseases | sialic acid | sialylated glycans | macrophages P rions are proteinaceous infectious agents that lack nucleic acids (1, 2) . Mammalian prions replicate by recruiting the normal cellular form of the prion protein (PrP), denoted as PrP C , and converting it into the disease-associated form, denoted as PrP Sc (3) . Although the central nervous system (CNS) represents the main site of PrP Sc replication and deposition, PrP Sc is also found in peripheral organs, including cells and organs of the lymphoreticular system (4-7). Not only does PrP Sc colonize secondary lymphoid organs (SLOs), the germinal centers of spleen and lymph nodes offer suitable environments for replicating PrP Sc autonomously from the CNS (8) (9) (10) (11) . Prion colonization and replication in SLOs is important for several reasons. First, for prions acquired via peripheral routes, colonization of SLOs precedes invasion of the CNS (12) (13) (14) . Second, SLOs are more permissive to prions acquired via cross-species transmission than the CNS (15) . As such, the lymphoreticuar system represents a silent reservoir of infection, where prions could hide undetected while imposing a high risk of transmission through blood donation (16, 17) . Finally, chronic inflammation could expand distribution of prions to inflamed tissues that are usually not affected by prions under normal conditions (18, 19) . PrP C is a sialoglycoprotein in which terminal sialic acids are attached to galactose residues of two N-linked glycans via α2-3 and α2-6 linkages (20) (21) (22) . The ratio of diglycosylated to monoglycosylated and unglycosylated PrP C glycoforms increases with neuronal differentiation (23) , yet the role of N-linked glycans and their sialylation for PrP C function is unknown. Upon conversion to PrP Sc , the posttranslational modifications of PrP C , including its N-linked glycans, are carried over, giving rise to sialylated PrP Sc (24, 25) . The sialylation status of brain-derived PrP Sc was found to closely resemble that of PrP C (25) . In mammals, sialic acids are the most abundant terminal residues of cell membrane glycans. Sialic acids play an essential role in a broad range of cellular functions, but are especially important for neuronal plasticity and immunity (26) . Among other functions, sialic acids on the surface of mammalian cells act as a part of a "self-associated molecular pattern," helping the immune system to recognize "self" from "altered self" or "nonself" (27) . A decline in sialic acid content represents one of the molecular signatures of "apoptotic-cell-associated molecular patterns" found in apoptotic or aging cells (28, 29) . Removal of sialic acids from cell surface glycans exposes galactose residues that generate "eat me" signals for professional and nonprofessional macrophages. Examples include clearance of erythrocytes or platelets with reduced sialic acid residues by Kupffer cells (30, 31) or apoptotic neurons by microglia (32, 33) . Pathogens without sialic acids are more likely to be detected as foreign, by virtue of recognition of their nonsialylated glycans that contribute to "pathogen-associated molecular patterns" and also because of the lack of the protective effects of sialic acids (34) . In a striking illustration of molecular mimicry, a number of bacterial pathogens, including Escherichia coli K1 and group B Streptococcus, evolved enzymes to synthesize and express host-like sialic acids on their surfaces (34) . Although ∼20% of the prokaryotic genomes sequenced evolved genes responsible for biosynthesis of sialic acids or their analogs (35) , a number of pathogens, including Trypanosoma cruzi, Corynebacterium diphtheriae,
Significance
In mammals, sialic acids are the most abundant terminal residues on cell-surface glycans and comprise "self-associated molecular patterns," which protect the host from inappropriate activation of multiple immune pathways. In a striking illustration of molecular mimicry, a number of microbial pathogens recruit host sialic acids to decorate their surfaces and hide from the same immune responses. Prions are proteinaceous infectious agents, not conventional pathogens. This study found that sialylation of prions is enhanced upon their colonization of secondary lymphoid organs, via extracellular host sialylation machinery. Thus, prions may use strategies similar to other pathogens to camouflage themselves from the immune system, facilitating host invasion.
Hemophilus influenzae, Niesseria meningitides, and others, recruit host sialic acid or its precursor to decorate their surfaces, presumably to hide from the immune system (34) .
In 
PrP
Sc particles are multimers that range greatly in size (36) . To compare sialylation states of spleen-and brain-derived PrP Sc , scrapie materials were treated with proteinase K (PK) to remove PrP C , then denatured and analyzed by 2D gel electrophoresis (2D) (Fig. S1 ). In 2D, individual PrP molecules are separated according to their net charge in horizontal dimension. In PrP, each of the two N-linked glycans can carry up to five terminal sialic acid residues (21, 25) , while an additional single sialic acid could be present on the glycosylphosphatidylinositol (GPI) anchor (37) . Because individual PrP molecules contain from 0 to 10 sialic acids on their glycans, scrapie material is expected to display substantial charge heterogeneity (38) . Indeed, PK-treated and denatured scrapie material showed multiple charge isoforms for both diglycosylated and monoglycosylated glycoforms ( Fig. S1 and Fig. 1 A-E). Several charge isoforms were also seen for unglycosylated forms, a heterogeneity that is primarily attributed to the structural heterogeneity of the GPI-anchor ( Fig. S1 and Fig. 1 A-E) (37). Nevertheless, as expected, the distribution of diglycosylated and monoglycosylated charged isoforms were shifted toward acidic pH relative to unglycosylated isoforms, and the heterogeneity of diglycosylated and monoglycosylated isoforms was much higher than that of unglycosylated forms. Both features are in agreement with glycan sialylation.
Animals were infected intracranially with mouse-adapted strains RML, ME7, and 22L; hamster-adapted strain 263K; or synthetic strain S05 (39) , and their brain-and spleen-derived materials were analyzed by using 2D. Comparison of brainderived materials revealed only minor strain-or species-specific differences in charged isoform distribution patterns ( Fig. 1 A-E) . Remarkably, regardless of the strain-or species-specific differences, brain-derived PrP Sc glycoforms displayed a broader charge distribution than spleen-derived PrP Sc , whereas spleen-derived diglycosylated glycoforms were shifted toward acidic pH relative to those of brain-derived glycoforms ( Fig. 1 A-E) . In contrast to diglycosylated glycoforms, unglycosylated glycoforms from spleen-derived material did not show acidic shift relative to the unglycosylated glycoforms from brain-derived material. With unglycosylated forms serving as internal references, acidic shift of diglycosylated isoforms indicates that the sialylation level of spleen-derived PrP Sc was higher than that of brain-derived PrP Sc . In animals inoculated intraperitoneally (i.p.), the sialylation patterns of spleen-or brain-derived PrP Sc were very similar to those observed for animals inoculated intracranially, arguing that the spleen-specific sialylation pattern did not depend on the inoculation route (Fig. 1A) . The spleen-and brain-specific 2D patterns were highly reproducible within animal groups inoculated with the same strains (Fig. S2) .
Differences in lengths of PK-resistant cores of PrP Sc deposited in brain and spleen could contribute to differences in tissue-specific patterns of charged isoforms. PK cleaves PrP Sc at multiple sites located within residues 74-102 (40, 41) . Although distribution of sites is largely dependent on strain-specific structure, other parameters such as cleavage conditions and PK concentration could also affect site distribution (41, 42) . Because the pI values of unglycosylated forms were the same for brain-and spleen-derived materials ( Fig. 1 A-E) , it is unlikely that differences in pI distribution of diglycosylated and monoglycosylated forms were due to different PK cleavage sites. Nevertheless, to determine the extent to which distribution of charge isoforms could be affected by digestion conditions, 263K brain-derived material was treated with 2, 20, or 200 μg/mL PK. An increase in PK concentration did not change the distribution of charge isoform on 2D (Fig. S3A) brain-and spleen derived materials exist, it is highly unlikely that such differences account for tissue-specific differences in 2D patterns. To make sure that differences in charge distribution of brain-and spleen-derived materials were not due to the procedure used for preparation of spleen-derived PrP (Fig. S3B) . Finally, to confirm that charge distribution on 2D reports on sialylation status, brain-and spleen-derived materials were treated with acetic acid (Fig. S3C) or Arthrobacter ureafaciens sialidase (Fig. S3D) , according to the protocols that remove sialic acid residues chemically or enzymatically, respectively. As expected, the charge distributions shifted toward basic pH in both brain-and spleen-derived materials in both control experiments ( Fig. S3 C and D) . In summary, the above experiments established that brain-and spleen-derived prions are different with respect to their sialylation status. Sc particles-i.e., particles sialylated above or below statistically averaged level-exist. The first hypothesis was not supported by previous data illustrating that spleen-expressed PrP C was equally or even less sialylated than brain-expressed PrP C (38) . To test the second and third hypotheses, we asked whether the sialylation status of PrP Sc changes upon colonization of SLOs. Wild-type mice were inoculated i.p. by using brain-derived 263K, and sialylation status of PrP Sc sequestered by cells of the peritoneal cavity, spleen, and mediastinal lymph nodes was tested 6 or 24 h after injection. Hamster-adapted strain 263K was used for inoculating mice to avoid interference due to immediate replication of mouse prions in mouse SLOs (43) .
Relative to the charge isoform distribution of injected material, PrP Sc recovered from all three sites (spleen, lymph nodes, and peritoneal cavity) showed isoform distribution shifted toward acidic pH on 2D by 24 h (Fig. 3 ). To analyze individual sialylation profiles, diglycosylated charge isoforms were separated arbitrarily into two categories, as described in Materials and Methods. Isoforms located toward acidic pH from pI 7.5 were designated as hypersialylated, and those toward basic pH were designated as hyposialylated (Fig. S1 ). The percentage of sum intensities of hypersialylated diglycosylated isoforms was used to estimate whether the shifts were statistically significant. PrP
Sc from spleen showed a more substantial shift than PrP Sc sequestered by peritoneal cells or lymph nodes. Nevertheless, for all three sites, the shift toward acidic pH was statistically significant by 24 h after injection (Fig. 3 ). This result is in agreement with the hypothesis that PrP Sc sequestered in SLOs is a substrate of STs and undergoes enhanced sialylation (Fig. 2B ). However, this result cannot exclude the third hypothesis, according to which the acidic shift is due to faster clearance of PrP Sc particles with low sialylation levels than particles with high sialylation levels (Fig. 2C) .
If subpopulations of differentially sialylated PrP Sc particles exist, they are expected to display a broad range of net charges. To test this, cation-and anion-exchange resins were used to isolate differentially charged and, therefore, differentially sialylated, PrP Sc particles. Scrapie material was incubated with ion-exchange resins and then eluted by using increasing concentrations of NaCl (Fig. S4A ). Peaks were eluted at 1.2 or 1.6 M NaCl from anionor cation-exchange resins, respectively, and analyzed by using 2D. High concentrations of salt were required for eluting PrP Sc , indicating that sorbtion of PrP Sc to the resins was strong and depended on electrostatic interactions. Nevertheless, no differences with respect to the sialylation pattern were observed between materials eluted from cation-or anion-exchange resins on 2D (Fig. S4A) . In previous studies, PrP Sc produced in Protein Misfolding Cyclic Amplification using desialylated PrP C was found to be more sensitive to PK treatment than brain-derived PrP Sc (38) . We speculated that, if differentially sialylated PrP Sc particles exist, they might have different physical properties, such as solubility or PK resistance. If this hypothesis is the case, fast proteolytic clearance of soluble, proteolytically sensitive PrP Sc subfractions in SLOs could account for the acidic shifts on 2D. To test this hypothesis, 263K brain material was subjected to ultracentrifugation, and then the pellet and supernatant were analyzed by 2D. The distribution of charge isoforms was remarkably similar for PrP Sc particles in both the pellet and supernatant (Fig. S4B ). By using an alternative format, RML brain material was centrifuged according to the protocol that separates PK-sensitive and -resistant PrP Sc particles (Fig. S4C) . Again, no notable differences were observed in the distribution of charge isoforms between PKsensitive and -resistant PrP Sc (Fig. S4C) . In summary, these results did not support the hypothesis that differentially sialylated PrP 
To test whether PrP
Sc sialylation observed in vivo can be recapitulated in vitro, mouse splenocytes and peritoneal cells were isolated and cultured in vitro. Because macrophages are known to sequester and transport PrP Sc to SLOs, the mouse macrophage RAW cell line was used in parallel experiments. Brain-derived PrP Sc material was incubated with primary splenocytes, peritoneal cells, or RAW cells for 2 h, then cells were washed, medium was replaced (this time point is designated as 0 h), and the cells were cultured in fresh medium for 24 or 48 h. The distribution of PrP Sc charge isoforms on 2D exhibited a notable, statistically significant shift toward acidic pH after 24 and 48 h in all cultured cells in comparison with the 0-h time points (Fig. 4 A-D) . To make sure that this acidic shift was not due to a spontaneous "aging" or enzymatic activity that might be present in FBS, PrP Sc was incubated in PBS alone or in the presence of FBS for 48 h in the absence of cells and assayed by 2D. No change in sialylation pattern was observed on 2D after 48 h of incubation in PBS or FBS (Fig. S5A) . To rule out the possibility that PrP Sc sialylation is due to sialyltransferases released by dead or spontaneously lysed cells, brain-derived PrP Sc was incubated with cell medium collected after culturing confluent RAW cells for 48 h. Again, no change in sialylation pattern was observed on 2D (Fig. S5B) . In another control experiment, brain-derived PrP Sc materials were incubated with N2a cells, which are of neuronal origin, and probed by 2D. After 48 h of incubation, a very minor shift in the charge distribution was noticed, which was not statistically significant (Fig. S5C) . These experiments established that the shift of PrP Sc glycoforms toward acidic pH was due to cellassociated enzymatic activity and specific to splenocytes, peritoneal cells, or macrophages.
Peritoneal cells
Lymph nodes To confirm that the acidic shift in distribution of PrP Sc glycoforms was due to ST activity, two general ST inhibitors, CTP and peracetylated 3F ax -Neu5Ac (FPN), were used (44) (45) (46) (47) (48) (49) . In the absence of inhibitors, the distribution of PrP Sc charge glycoforms showed statistically significant shift toward acidic pH after incubation with RAW cells or primary splenocytes for 24 h as before (Fig. 5 A and B) . However, in the presence of CTP or FPN, the changes in glycoform distribution patterns were very minor, if any, and not statistically different in comparison with the distribution at the 0-h time point (Fig. 5 A and B) . This experiment confirmed that the shift in PrP Sc glycoform distribution depends on genuine sialyltransferase activity.
RAW Macrophages Exhibit Sialyltransferase Activity. STs were traditionally thought to localize exclusively in Golgi (50) . However, in a growing number of studies, ST activities were found on the surface of a wide variety of immune system cells (48, 49, (51) (52) (53) . To test whether RAW cells exhibit surface ST activity, we used a fluorescently labeled precursor of sialic acid, CMP-5-FITCneuraminic acid (CMP-5-FITC-NEU), which is a membraneexcluded and sialidase-resistant substrate (54) . In the presence of CMP-5-FITC-NEU, RAW cells exhibited considerable fluorescence (Fig. 6) . However, upon application of CTP, the fluorescence levels dropped more than fourfold (Fig. 6) . When RAW cells were pretreated with bacterial neuraminidase, an enzyme that cleaves α2-3-and α2-6-linked sialic acid residues from cell surface glycoproteins and glycolypids, the cell-associated CMP-5-FITC-NEU fluorescence was sevenfold higher relative to the cells not treated with neuraminidase (Fig. 6) . Remarkably, in the presence of CTP, the fluorescence level in neuraminidase-pretreated cells dropped by 30-fold from 80,220 to ∼2,603 (Fig. 6) . Although some of the fluorescence in the presence of CMP-5-FITC-NEU could be attributed to uptake and use of CMP-5-FITC-NEU by intracellular sialyltransferases, the strong effect of the ST inhibitor and pretreatment with bacterial neuraminidase argues that RAW cells display genuine ST activity on the cell surface. This result is consistent with previous studies that attributed CMP-5-FITC-NEU fluorescence to ST activity on the cell surface (48, 49) .
Discussion
The present study provides, to our knowledge, the first experimental illustration that the primary structure of PrP Sc -in particular, its sialylation status-is changed after conversion. Direct structural analysis of the N-linked glycoforms from spleenderived and in vitro-produced materials with enhanced sialylation will be needed in future studies to define the details of what exactly is occurring. Nevertheless, enhanced sialylation of PrP Sc was observed in SLOs regardless of prion strain, host species, or inoculation route tested. The alternative explanations to the hypothesis on postconversion sialylation are (i) that spleenexpressed PrP C is sialylated at a higher level than the brainderived PrP Sc or (ii) fast metabolic clearance of PrP Sc particles with low sialylation levels in SLOs (Fig. 2 A and C) . The first alternative was not supported by the previous studies (38 , which is highly unlikely. Finally, experiments with sialyltransferease inhibitors linked the acidic shift of charged isoform distribution to sialyltransferase activity. Because sialylation plays multiple roles in immunity (26, 34) , the present finding that spleen-deposited PrP Sc is sialylated at higher levels than brain-derived PrP Sc has broad implications. Prions are not conventional pathogens, yet sialylation of prions in SLOs displays remarkable parallels with molecular mimicry of microbial pathogens. A number of pathogens decorate their surfaces by using host sialic acid in an attempt to hide from the immune system (34) . Surfaces of mammalian cells and glycoproteins in blood circulation are densely sialylated (26) . Sialylation represents a part of the self-associated molecular pattern used by cells of the immune system for recognizing self from altered self or nonself (28, 34) . Similar to molecular mimicry of microbial pathogens, sialylation of prions in SLOs might play a similar role. This mechanism could be particularly important for cross-species prion transmission between mammals and human. Because of an irreversible mutation in the gene encoding N-acetylneuraminic acid hydroxylase that occurred during evolution from primates to human, the type of sialic acid produced in peripheral tissues of humans (N-acetyl neuraminic acid; Neu5Ac) is different from the type synthesized by other mammalian species (N-glycolylneuraminic acid; Neu5Gc) (55) . As a result, human-specific differences evolved in the binding sites of human Siglecs, the family of sialic acidbinding proteins, for selective recognition of Neu5Ac over Neu5Gc (55) . It is not known whether differences in the type of sialic acid contribute to the species barrier of prion transmission between animals and human. Nevertheless, it is tempting to speculate that upon cross-species transmission of prions to humans, enhanced sialylation of PrP Sc "humanizes" prions of nonhuman origin, helping them to deceive the immune system.
Transmission of prions between species is more difficult than within the same species because of the species barrier. Remarkably, lymphoid tissues were found to be more susceptible to cross-species prion transmission than nerve tissues (15) . Although the mechanisms behind high permissiveness of lymphoid tissues to prions are not known, prions acquired via cross-species transmission can persist stably and silently in SLOs for a long time in the absence of neuroinvasion (15, 56, 57) . Aged animals that are known to be less susceptible to prion infection than young animals can also accumulate prions within their lymphoid tissues, despite lack of prions in their brains (58) . Moreover, the lymphoid tissues display a higher capacity than nerve tissues to replicate prions after low-dose infection (59) . The subclinical disease acquired via cross-species transmission or with low prion doses might never lead to neuroinvasion or clinical disease. Nevertheless, colonization of SLOs by prions poses a real risk due to the possibility of silent spread of infection through donation of blood or organs or infected surgical instruments (16, 56, 57, 60) . The higher permissiveness of lymphoid tissues than the CNS is very surprising, considering that the expression level of PrP C in lymphoid tissues is substantially lower than in brain (61) (62) (63) (64) and that lymphoid cells are specialized in recognizing and degrading pathogens. Bearing in mind that sialylation status controls the lifetime of glycoclusters in blood circulation (65), our study suggests that enhanced sialylation of PrP Sc in SLOs might contribute to the high permissiveness of lymphoid tissues to prions.
There are a number of mechanisms by which sialylation protects pathogens from the host (27) . Among them is recruitment of factor H that dampens activation of alternative complement pathways by recognizing molecular patterns containing sialic acids on surfaces of host cells or pathogens (66, 67) . Alternative mechanisms involve engaging inhibitory Siglecs (sialic acid recognizing Ig-like lectins) that likewise recognize sialic acid patterns and suppress innate immune cells (68, 69) . In addition, sialylation can mask glycan ligands for Gal/GalNAc receptors or for galectins, a family of secreted proteins that recognize galactose and its derivatives (70) . Finally, sialylation of glycans on the pathogen surface can inhibit production and/or binding of antibodies against asialoglycans (55) . Of these four mechanisms, the first three could contribute to protection of prions due to enhanced PrP Sc sialylation in SLOs. Several types of cells-including macrophages, monocytes, B lymphocytes, and dendritic cells-capture prions at initial entry sites and transport them to SLOs (43, (71) (72) (73) . In addition to trafficking of prions to SLOs, macrophages play a role in degrading prions (74) (75) (76) (77) . The present study suggests that, in addition to transporting and degrading prions, macrophages are also involved in sialylating PrP Sc . Indeed, in vivo changes in sialylation patterns were observed in the peritoneal cavity, lymph nodes, and spleen-the sites with considerable populations of macrophages. Similar changes in PrP Sc sialylation were also observed in vitro upon incubation of PrP Sc with primary splenocytes or macrophage RAW cells. RAW cells showed significant ST activity on their surfaces. ST activity has also been found on the surface of dendritic cells and lymphocytes (48, 49) . Considering that a number of cells of immune system-including B lymphocytes, monocytes, plasmacytoid dendritic cells, natural killer cells, and others-sequester and disseminate PrP Sc (43, 72, 78) , it is likely that sialylation of PrP Sc is not limited to macrophages.
Although degradation of PrP
Sc by macrophages has been well established, the present study suggests that macrophages might also play a protective role by enhancing sialylation of PrP Sc in parallel to their role in degrading PrP Sc . In a recent study, Siglec-1 (CD169) expressed on the surface of primary microphages was shown to be responsible for capturing sialylated viral pathogens and facilitating their intercellular transfer (79) . It would be worth testing the possibility that enhanced sialylation of PrP Sc in SLOs could also facilitate their intercellular transfer.
The present work suggests that enhanced sialylation of PrP Sc occurs on the cell surface rather than intracellularly. Traditionally, STs were thought to localize exclusively within the intracellular secretory apparatus (50) . A growing number of studies report ST activity in serum or on surfaces of the cells of immune system, including polymorphonuclear leukocyte, monocyte-derived dendritic cells, lymphocytes, and T cells (48, 49, (51) (52) (53) 80) . Presence of ST on the cell surface or in serum allows rapid restoration or remodeling of the sialylation status of cells without de novo synthesis of cell surface glycoconjugates (48, 49, 81) . ST expression and sialylation of cell surfaces are finely regulated during cell maturation, differentiation, and inflammation (48, 49, 81) . Notably, systemic inflammatory response involves secretion of STs into serum, a process that modulates the inflammatory response (48, (81) (82) (83) . It would be interesting to determine whether extracellular STs contribute to prion colonization of inflamed tissues via altering the sialylation status of PrP Sc . Because the family of mammalian STs includes 20 enzymes that have redundant specificity (84), identifying those that are involved in enhancing sialylation of PrP Sc would involve considerable effort.
If PrP Sc is a subject of extracellular sialylation in SLOs, it is not clear why PrP C , which is expressed on a cell surface, is not targeted by extracellular STs to the same extent as PrP Sc . In mouse-derived primary splenocytes, the half-life of PrP C was found to be only 1.5-2 h (85), which is much shorter than the half-life of PrP Sc . In addition, the population of cells that express PrP C could be different from the population of cells that express cell surface STs. In spleen and lymph nodes, PrP C is primarily expressed by follicular dendritic cells (10) , which are resident cells of germinal centers and different from dendritic cells of myeloid origin. It is not known whether follicular dendritic cells express cell surface STs.
Materials and Methods
Scrapie Materials. Weanling Golden Syrian hamsters or C57BL/6NHsd mice were inoculated intracranially or i.p. under 2% O 2 /4 minimum alveolar concentration isoflurane anesthesia by using scrapie brain homogenates of hamster-or mouse-adapted strains, respectively. Animals were euthanized at the terminal stage of the disease, and organs were collected for 2D analysis. This study was carried out in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health (86) . The animal protocol was approved by the Institutional Animal Care and Use Committee of the University of Maryland, Baltimore (Assurance no. A32000-01; Permit no.: 0215002).
Preparation of Brain and Spleen Materials for 2D. We prepared 10% (wt/vol) scrapie brain or spleen homogenates in PBS by using glass/Teflon homogenizers attached to a cordless 12-V compact drill (Ryobi) as described (87) . For 2D electrophoresis of brain-derived material, an aliquot of 10% (wt/vol) homogenate was diluted with nine volumes of 1% (wt/vol) Triton X-100 in PBS, sonicated for 30 s inside Misonix S-4000 microplate horn (Qsonica), and treated with 20 μg/mL PK (New England BioLabs) for 30 min at 37°C. For 2D electrophoresis of spleen-derived material, 250 μL of 10% (wt/vol) homogenate was diluted 1:1 with PBS, aliquotted into 0.2-mL thin-wall PCR tubes, sonicated for 30 s inside Misonix S-4000 microplate horn, and combined in one tube, which was subjected to a 30-min centrifugation at 16,000 × g at 4°C. The pellet was resuspended in 25 μL of 1% (wt/vol) Triton in PBS and treated with 20 μg/mL PK for 30 min at 37°C. Resulting brain or spleen samples were supplemented with 4× SDS loading buffer, heated for 10 min in a boiling water bath, and processed for 2D electrophoresis as described below.
Performance of 2D Electrophoresis. Samples of 25-μL volume prepared in loading buffer as described above were solubilized for 1 h at room temperature in 200 μL of solubilization buffer [8 M urea, 2% (wt/vol) CHAPS, 5 mM TBP, 20 mM Tris, pH 8.0), alkylated by adding 7 μL of 0.5 M iodoacetamide, and incubated for 1 h at room temperature. Then, 1,150 μL of ice-cold methanol was added, and samples were incubated for 2 h at −20°C. After centrifugation at 16,000 × g at 4°C, supernatant was discarded, and the pellet was resolubilized in 160 μL of rehydration buffer [7 M urea, 2 M thiourea, 1% (wt/vol) DTT, 1% (wt/vol) CHAPS, 1% (wt/vol) Triton X-100, 1% (vol/vol) ampholyte, and trace amount of Bromophenol Blue]. Fixed immobilized precast IPG (immobilized pH gradient) strips [catalog (cat.) no. ZM0018; Life Technologies] with a linear pH gradient 3-10 were rehydrated in 155 μL of resulting mixture overnight at room temperature inside IPG Runner cassettes (cat. no. ZM0008; Life Technologies). Isoelectrofocusing (first dimension separation) was performed at room temperature with rising voltage (175 V for 15 min, then 175-2,000-V linear gradient for 45 min, and then 2,000 V for 30 min) on Life Technologies Zoom Dual Power Supply using the XCell SureLock MiniCell Electrophoresis System (cat. no. EI0001; Life Technologies). The IPG strips were then equilibrated for 15 min consecutively in (i) 6 M urea, 20% (vol/vol) glycerol, 2% SDS, 375 mM Tris·HCl, pH 8.8, 130 mM DTT, and (ii ) 6 M urea, 20% (vol/vol) glycerol, 2% SDS, 37 5mM Tris·HCl, pH 8.8, and 135 mM iodoacetamide, and loaded on 4-12% Bis-Tris ZOOM SDS/PAGE precast gels (cat. no. NP0330BOX; Life Technologies). For the second dimension, SDS/PAGE was performed for 1 h at 170 V. Immunoblotting was performed as described elsewhere; blots were stained by using 3F4 (cat. no. SIG-39600; Covance) antibody for hamster and ab3531 antibody (Abcam) for mouse tissues. To determine a specific 2D pattern and to check reproducibility of the procedure, at least two brains or spleens from for each animal group were analyzed.
Desialylation of PrP
Sc with Acetic Acid. PK-treated brain and spleen materials were prepared as for 2D electrophoresis. PK digestion was stopped by addition of 5 mM PMSF, then the samples were denatured by incubating for 10 min at 95°C in the presence of 0.5% SDS and 40 mM DTT, followed by the addition of 1% (vol/vol) Nonidet P-40. Then the samples were supplemented with 1% (vol/vol) acetic acid and incubated at 100°C for 1 h with 1,000 rpm shaking in Eppendorf thermomixer to achieve mild acid hydrolysis of sialic acids (80) . Mock-treated samples were denatured by the same procedure, but not treated with acetic acid.
Sc with Sialidase. We diluted 10% (wt/vol) scrapie brain and spleen materials 10-fold in 1× PBS supplied with 1% (vol/vol) Triton X-100 and supplemented with 25 μg/mL PK. After 30 min at 37°C, PK digestion was stopped by the addition of 5 mM PMSF. Then the samples were denatured by incubating for 10 min at 95°C. The subsequent treatment with Arthrobacter ureafaciens sialidase (cat. no. P0722L; New England Biolabs) was as follows. After addition of 10% (vol/vol) sialidase buffer GlycoBuffer1 supplied by the enzyme manufacturer, 200 units/mL sialidase were added, followed by incubation on a shaker at 37°C for 10-12 h. Mocktreated samples were processed by the same procedure, but not supplied with the sialidase.
Ion-Exchange Chromatography. We diluted 10% (wt/vol) 263K brain homogenates 10-fold in 25 mM Tris, pH 7.4, buffer supplied with 1% (wt/vol) Triton X-100 and sonicated for 30 s at 170 W energy output in the microplate horn (Misonix S-4000). The samples were then incubated with PK (10 μg/mL, 37°C, 1 h) (cat. no. P8107S; New England Biolabs). The digestion was stopped by adding 2 mM PMSF. The samples were filtered through a 22-μm syringe filter (cat. no. SLGV033RB; Millipore). The cation or anion exchange mini columns (cat. no. 90008 and 90010, respectively; Thermo Scientific) were pre-equilibrated with Tris pH 7.4 and loaded with 400 μL of scrapie material prepared as described above, and centrifuged at 2,000 × g for 5 min. Then the columns were washed with 400 μL of Tris pH 7.4 buffer and centrifuged at 2,000 × g for 5 min. The columns were then washed consecutively with 400-μL volumes of the following concentrations of NaCl: 0.4, 0.8, 1.2, and 1.6 M prepared in Tris, pH 7.4. The material was collected by centrifugation, supplied with SDS sample buffer, heated for 10 min in a boiling water bath, and analyzed by SDS/PAGE or 2D electrophoresis.
Ultracentrifugation. We solubilized 10% (wt/vol) 263K brain homogenates by addition of 9 volumes of 10% (wt/vol) sarkosyl in PBS and sonication for 30 s inside a Misonix S-4000 microplate horn. The samples were precleared by 2 min centrifugation at 500 × g in a tabletop centrifuge, and then 100 μL of the supernatant were diluted with 900 μL PBS and centrifuged for 20 min at 20°C at 32,400 rpm by using a TLA 100.3 rotor in an Optima TLX microultracentrifuge (Beckman). The supernatant containing solubilized PrP Sc and the pellet containing insoluble PrP Sc were collected. The pellet was resuspended in 200 μL of 1% (wt/vol) sarkosyl in PBS, treated with 20 μg/mL PK for 30 min at 37°C, and supplemented with 4× SDS sample buffer. A total of 60 μL of the supernatant were treated with 20 μg/mL PK for 30 min at 37°C, and concentrated by precipitation with 4 volumes of ice-cold acetone, incubated overnight at −20°C and subsequently centrifuged for 30 min at 16,000 × g. The resulting pellet was resuspended in 1× SDS loading buffer.
Separation of PK-Sensitive and -Resistant PrP

Sc
. We solubilized 10% (wt/vol) RML brain homogenates by addition of 9 volumes of 10% (wt/vol) sarkosyl in PBS and sonication for 30 s inside Misonix S-4000 microplate horn. The samples were precleared by 2 min centrifugation at 500 g in a tabletop centrifuge, and then 100 μL of the supernatant was diluted with 900 μL of PBS and centrifuged for 90 min at 16,000 × g at 4°C. The supernatant containing solubilized PrP Sc and the pellet containing insoluble PrP Sc were collected. The pellet was resuspended in 50 μL of 1% (wt/vol) sarkosyl in PBS, treated with 20 μg/mL PK for 30 min at 37°C, and supplemented with 4× SDS loading buffer. A total of 60 μL of the supernatant was treated with 2 or 20 μg/mL PK for 30 min at 37°C, concentrated by precipitation with 4 volumes of ice-cold acetone, incubated overnight at −20°C, and subsequently centrifuged for 30 min at 16,000 × g. The resulting pellet was resuspended in 1× SDS loading buffer.
IP Inoculation of Scrapie Material and Harvest of SLOs. We diluted 10% (wt/vol) 263K brain homogenate by using sterile PBS to a final concentration of 4% (wt/vol). A total of 500 μL per animal was injected i.p. into 4-wk-old C57BL/6NHsd mice by using 1-mL syringes with a 26-gauge needle (cat. no. 309625; BD Biosciences). After 6, 24, or 48 h after inoculations, spleens, mediastinal lymph nodes, and peritoneal cavity cells were collected. Spleens were homogenized to make 10% (wt/vol) tissue suspension in PBS with protease inhibitors (cOmplete, Mini, EDTA-free; cat. no. 04693159001; Roche) using glass/Teflon homogenizers. A total of 200 μL of 10% (wt/vol) spleen homogenate was diluted twice in PBS, sonicated for 30 s using Misonix S-4000 microplate horn sonicator and centrifuged at 16,000 × g, for 30 min at 4°C. The pellet was collected and resuspended in 50 μL of PBS with 1% (wt/vol) Triton X-100 and 1 mM EDTA, then digested with PK (20 μg/mL, 37°C, 30 min) and precipitated by acetone overnight as described above. The pellet was collected and dissolved in 30 μL of 1xSDS loading buffer, heated for 10 min in a boiling water bath and analyzed by 2D. Cells from the peritoneal cavity were collected and lysed as 1 × 10 6 cells per 200 μL of Mammalian Protein Extraction Reagent (M-PER) lysis buffer (cat. no. 78501; Thermo Scientific); the lysate was digested with PK (20 μg/mL, 37°C, 30 min) and concentrated threefold by acetone precipitation. The pellet was dissolved in 1× SDS loading buffer, heated for 10 min in a boiling water bath, and analyzed by 2D. For mediastinal lymph nodes, the residual connective tissue was removed, and nodes were homogenized in PBS, 1% (wt/vol) Triton X-100, 1 mM EDTA with protease inhibitors using bead beater (Model 2412PS-12W-B30; Biospec Products) and 0.1-mm glass beads (cat. no. 11079101; Biospec Products). This suspension was centrifuged at 200 × g for 1 min to remove beads; supernatant was collected and digested with PK (20 μg/mL, 37°C, 30 min). PrP Sc in lymph node samples was enriched sixfold by acetone precipitation, and the enriched lysates were denatured in 1× SDS loading buffer, heated for 10 min in a boiling water bath, and analyzed by 2D. The experiment was repeated twice using two mice for each time point in each experiment.
Isolation of Mouse Primary Splenocytes. Healthy 5-wk-old female C57BL/ 6NHsd mice were euthanized with CO 2 inhalation. Dissected spleens were transferred to a 10-cm cell culture dish containing 10 mL of cold PBS with 2 mM EDTA and homogenized by using a plunger of a 5 mL syringe. Cell suspensions were collected in 15-mL tubes and centrifuged at 1,500 × g for 5 min. Red blood cells from the pellet were lysed by using RBC lysis buffer (cat. no. R7757; Sigma) as described by the manufacturer, then the cells were resuspended in cell culture medium DMEM (cat. no. A total of 90 μL of each lysate was treated with 20 μg/mL PK for 30 min at 37°C under moderate shaking followed by precipitation overnight with acetone at −20°C. Precipitated materials were centrifuged for 30 min at 16,000 × g at 4°C. Pellets were air dried, dissolved in 30 μL of 1× SDS loading buffer, heated for 10 min in a boiling water bath, and analyzed by 2D.
In experiments with ST inhibitors, RAW 264.7 cells were incubated with 0.1% (wt/vol) 263K brain homogenate for 2 h and then washed as described above, and then CTP (cat. no. SIG-C1506; Sigma) or 3F ax -peracetyl Neu5Ac (cat. no. 566224; Millipore) was added to the medium to a final concentrations of 2 mM or 128 μM, respectively. Cells were cultured for 24 h in the presence of inhibitors and then harvested and analyzed as described above.
Flow Cytometry Analysis of ST Activity on RAW Cells. A fluorescent precursor CMP-5-FITC-NEU was prepared and used as described with minor modifications (48, 49, 88) . RAW cells were suspended at 5 × 10 5 cells per 100 μL of serum-free medium. For neuraminidase treatment, cells were suspended at 5 × 10 6 per mL into 300 μL of serum free medium and treated with 200 unit/mL
Clostridium perfringens neuraminidase (α2-3,6,8 neuraminidase, cat. no. P0720L; New England Biolabs) for 90 min at 37°C in CO 2 incubator. After treatment, cells were washed with serum-free medium and divided into tubes containing 100 μL of serum-free medium at a density of 5 × 10 5 cells per tube. CMP-5-FITC-NEU was added to neuraminidase-treated or untreated cells to a final concentration of 10 μM, and cells were incubated for 2 h at 37°C in a CO 2 incubator with gentle intermittent shaking. In experiments with ST inhibitor, neuraminidase-treated or nontreated RAW cells were incubated with 5 mM CTP for 30 min before addition of CMP-5-FITC-NEU, and 5 mM CTP was maintained in culture medium during 2-h incubations with CMP-5-FITC-NEU. After incubation with CMP-5-FITC-NEU, 1 mL of cold serum-free medium was added to cells, and the cells were washed with serum-free medium to remove unbound fluorescent precursor. Cells were centrifuged at 1,000 × g for 3 min, and then the pellet was collected and suspended in 400 μL of PBS with 1% (wt/vol) BSA and 2 mM EDTA for FACS analysis. Cells, untreated with neither neuraminidase nor CMP-5-FITC-NEU, served as an autofluorescence control. The data were collected on FITC channel by using a BD FACS CANTO II instrument and analyzed by using Flow Jo software (Version 8.8.7).
Statistical Analysis of Sialylation on 2D. The 2D Western blot signal intensity was digitized for densitometry analysis by using AlphaView software (ProteinSimple). The 2D blots were aligned horizontally, and a line drawn at pI 7.5 was used to arbitrarily separate diglycosylated charge isoforms into hypersialylated and hyposialylated (Fig. S1 ). In the software window, a rectangle was drawn to confine the spots of interest, and the densities were measured. The intensity of an equal background area from the same blot was subtracted before calculations were performed. The acquired spot ensemble intensities were used to calculate percentage of "hypersialylated" isoforms. Hypersialylated isoforms were defined operationally as all isoforms located to the left of the pI-7.5 line; the percentage of hypersialylated isoforms was calculated assuming the total intensity of all isoforms as 100%. Results are presented as the mean ± SD. Statistical significance (P) between groups were calculated by Student's t test and is indicated in figures as * for significant (P < 0.05) and # for insignificant (P > 0.05) statistics.
